The cell cycle checkpoint inhibitors in the treatment of leukemias

@inproceedings{Rora2017TheCC,
  title={The cell cycle checkpoint inhibitors in the treatment of leukemias},
  author={A. Ghelli Luserna di Rora’ and Ilaria Iacobucci and Giovanni Martinelli},
  booktitle={Journal of Hematology & Oncology},
  year={2017}
}
The inhibition of the DNA damage response (DDR) pathway in the treatment of cancers has recently reached an exciting stage with several cell cycle checkpoint inhibitors that are now being tested in several clinical trials in cancer patients. Although the great amount of pre-clinical and clinical data are from the solid tumor experience, only few studies have been done on leukemias using specific cell cycle checkpoint inhibitors. This review aims to summarize the most recent data found on the… CONTINUE READING

References

Publications referenced by this paper.
SHOWING 1-10 OF 122 REFERENCES

Phase I Study of Single-Agent AZD1775 (MK-1775), a Wee1 Kinase Inhibitor, in Patients With Refractory Solid Tumors.

  • Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • 2015
VIEW 9 EXCERPTS
HIGHLY INFLUENTIAL

Mutation analysis of the DNA-damage Ghelli

WK Hofmann, CW Miller, +5 authors HP. Koeffler
  • Luserna di Rora’ et al. Journal of Hematology & Oncology
  • 2017